ストックスクリーナーアプリを入手
16.63
0.48%
-0.08
アフターアワーズ：
16.60
-0.03
-0.18%
前日終値:
$16.71
開ける：
$17.15
24時間の取引高:
4.03M
Relative Volume:
1.42
時価総額：
$1.84B
収益：
$70.92M
当期純損益:
$-342.21M
株価収益率:
-4.4177
EPS:
-3.7644
ネットキャッシュフロー:
$-304.30M
1週間 パフォーマンス:
+3.04%
1か月 パフォーマンス:
+3.29%
6か月 パフォーマンス:
-47.37%
1年 パフォーマンス:
+10.87%
1日の値動き範囲:
$16.45
$17.44
1週間の範囲:
$15.96
$17.44
52週間の値動き範囲:
$13.18
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Compare VRDN vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
16.63 | 1.84B | 70.92M | -342.21M | -304.30M | -3.7644 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-10 | 繰り返されました | Wedbush | Outperform |
| 2025-12-03 | 開始されました | William Blair | Outperform |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-08-25 | 再開されました | Jefferies | Buy |
| 2024-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 開始されました | TD Cowen | Buy |
| 2024-09-11 | 繰り返されました | Needham | Buy |
| 2024-06-11 | 開始されました | Wolfe Research | Outperform |
| 2024-06-06 | 開始されました | Goldman | Buy |
| 2024-05-09 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | 開始されました | BTIG Research | Buy |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-05-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-04-17 | 開始されました | Wells Fargo | Overweight |
| 2023-03-30 | 開始されました | Stifel | Buy |
| 2022-12-19 | 開始されました | Cowen | Outperform |
| 2022-12-19 | 開始されました | Needham | Buy |
| 2022-12-16 | 開始されました | Credit Suisse | Outperform |
| 2022-12-01 | 開始されました | H.C. Wainwright | Buy |
| 2022-06-23 | 開始されました | B. Riley Securities | Buy |
| 2021-11-18 | 開始されました | SVB Leerink | Outperform |
| 2021-10-12 | 開始されました | Evercore ISI | Outperform |
| 2021-01-25 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Viridian Therapeutics Inc (VRDN) 最新ニュース
(VRDN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Viridian Therapeutics Inc (VRDN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Viridian Therapeutics Inc (VRDN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Viridian Therapeutics Inc (VRDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Viridian Therapeutics Inc (VRDN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Viridian Therapeutics Inc (VRDN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Viridian Therapeutics Inc (VRDN) Institutional Confidence - TradingKey
Viridian Therapeutics Inc (VRDN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Viridian Therapeutics Inc (VRDN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Viridian Therapeutics Inc (VRDN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Goldman Sachs Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $35 - Moomoo
VRDN: Approval expected June 30, with launch-ready teams and strong clinical differentiation - TradingView
VRDN News | VIRIDIAN THERAPEUTICS INC (NASDAQ:VRDN) - ChartMill
Viridian Therapeutics stock tumbles after Amgen Tepezza data By Investing.com - Investing.com UK
Viridian Therapeutics stock tumbles after Amgen Tepezza data - Investing.com
VRDN: Ready for TED drug launch in 2026, aiming for broad access and major market expansion - TradingView
[8-K] Viridian Therapeutics, Inc.\DE Reports Material Event - Stock Titan
Viridian Therapeutics (VRDN) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Viridian ties up WuXi supply deal ahead of TED decision - The Pharma Letter
How Investors May Respond To Viridian Therapeutics (VRDN) Debt Repayment And WuXi Manufacturing Pact - Sahm
Viridian Therapeutics (VRDN) Edges Higher Amid Modest Trading ActivityInsider Buying Alerts - newsline.com
Viridian Therapeutics (NASDAQ: VRDN) retires $55.1M Hercules term loan years early - Stock Titan
Viridian Therapeutics to Present at Goldman Sachs and Jefferies Healthcare Conferences in June - geneonline.com
Viridian Therapeutics to Participate in Upcoming June 2026 Investor Conferences - BioSpace
(VRDN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Viridian Therapeutics to Participate in Upcoming June Investor Conferences - The Joplin Globe
Viridian Therapeutics secures WuXi deal for veligrotug manufacturing - The Globe and Mail
PDUFA decision nears as Viridian Therapeutics (VRDN) advances TED pipeline and reports Q1 results - MSN
According to documents submitted to the U.S. Securities and Exchange Commission (SEC), Viridian Therapeutics, Inc. has reached an agreement with WuXi Biologics, which will manufacture and supply Viridian's investigational drug Veligrotug. - Bitget
Viridian Therapeutics signs manufacturing deal with WuXi Biologics for thyroid eye disease drug - marketscreener.com
Viridian therapeutics enters commercial manufacturing agreement with Wuxi biologics on May 24, 2026 - marketscreener.com
Viridian (VRDN) secures WuXi Biologics pact for long-term veligrotug manufacturing - Stock Titan
Viridian Therapeutics, Inc. Enters Into Commercial Manufacturing Services Agreement With WuXi Biologics - marketscreener.com
Viridian Therapeutics(VRDN) Stock Options Chain | Quotes & News - Moomoo
Does Viridian’s Upsized Note and Equity Offering Change The Bull Case For Viridian Therapeutics (VRDN)? - Sahm
Viridian Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Thyroid Eye Disease PipelineAnalyst Consensus Shift - newsline.com
Viridian Therapeutics prices upsized $350M concurrent stock and convertible notes offerings - MSN
Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M - Insider Monkey
Viridian Therapeutics releases topline phase 3 TED data elegrobart - Eyes On Eyecare
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million - AOL.com
Viridian Therapeutics launches $250M concurrent debt and equity offerings - MSN
HighVista Strategies Sells 238,243 Shares of Viridian Therapeutics in Q1 2026News and Statistics - IndexBox
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million - The Motley Fool
Why is Viridian Therapeutics stock sinking Monday? - MSN
VRDN: Wedbush Maintains Rating but Lowers Price Target | VRDN St - GuruFocus
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $26 - Moomoo
Liquidity Mapping Around (VRDN) Price Events - Stock Traders Daily
VRDN Maintained by Evercore ISI Group -- Price Target Lowered to $26 - GuruFocus
Viridian Therapeutics Analyst Ratings and Price Targets | NASDAQ:VRDN - Benzinga
Viridian Therapeutics Inc (VRDN) Stock Price, Quote, News & History - Benzinga
Bellevue Group (VRDN) files Schedule 13G for 6.6% ownership - Stock Titan
Viridian Therapeutics Inc (VRDN) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):